Food and Drug Administration: Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine) Treatment of Symptomatic Botulism. BLA 125462. Briefing Document for the Biologic Products Advisory Committee.(PDF).
nih.gov
ncbi.nlm.nih.gov
Centers for Disease Control and Prevention: Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. In: MMWR. Morbidity and mortality weekly report. Band 59, Nummer 10, März 2010, ISSN1545-861X, S. 299, PMID 20300057.
zdb-katalog.de
Centers for Disease Control and Prevention: Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. In: MMWR. Morbidity and mortality weekly report. Band 59, Nummer 10, März 2010, ISSN1545-861X, S. 299, PMID 20300057.